Dosing and administration

1 HOUR ADMINISTRATION REGIMEN

BESPONSA® is administered as an IV infusion over 1 hour in 21 or 28-day cycles (on days 1, 8 and 15)1

  • Due to the risk of VOD for patients proceeding to HSCT, the recommended duration of treatment is 2 cycles. A third cycle may be considered for those patients who do not achieve CR/CRi and MRD negativity after 2 cycles1
  • Patients who do not achieve CR/CRi within 3 cycles should discontinue treatment1
  • For patients not proceeding to HSCT, a maximum of 6 cycles may be administered1

*Cycle 1 is 3 weeks in duration, but may be extended to 4 weeks if the patient achieves a CR/CRi, and/or to allow recovery from toxicity.1
CR, complete remission; CRi, complete remission with incomplete haematological recovery of peripheral blood counts; HSCT, haematopoietic stem cell transplant; IV, intravenous; MRD, minimal residual disease.

  1. BESPONSA® SmPC Summary of Marketing Product Characteristics

PP-INO-GBR-0132. May 2020

Additional administration information

 

*10,000/mm3

ALL, acute lymphoblastic leukaemia; PBC, peripheral blast count

  1. BESPONSA® SmPC Summary of Marketing Product Characteristics

PP-INO-GBR-0132. May 2020